Cancer Precision Medicine in China  by Li, Hui
Genomics Proteomics Bioinformatics 14 (2016) 325–328HO ST E D  BY
Genomics Proteomics Bioinformatics
www.elsevier.com/locate/gpb
www.sciencedirect.comMEETING REPORTCancer Precision Medicine in ChinaE-mail: lihui@tjmuch.com (Li H).
a ORCID: 0000-0002-3526-6664.
Peer review under responsibility of Beijing Institute of Genomics,
Chinese Academy of Sciences and Genetics Society of China.
http://dx.doi.org/10.1016/j.gpb.2016.10.002
1672-0229  2016 The Author. Production and hosting by Elsevier B.V. on behalf of Beijing Institute of Genomics, Chinese Academy of Scien
Genetics Society of China.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Hui Li 1,2,a1National Clinical Research Center for Cancer (Tianjin), Tianjin 300060, China
2Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, ChinaReceived 6 October 2016; accepted 8 October 2016
Available online 14 October 2016Background
Cancer, as a global health issue, has been attracting increasing
attention from scientists, medical professionals, as well as the
general population. During the past several decades, many
therapeutic approaches, including surgery, chemotherapy,
radiotherapy and immunotherapy, have come into play for
cancer treatment. Nonetheless, many of these treatments are
not personalized according to the specific situation or genetic
context of a particular patient. Nowadays, precision medicine,
defined by President Obama as ‘‘delivering the right treatments
at the right time—every time—to the right person”, opens a
new era of cancer research with the hope to provide personal-
ized treatment for different patients. To foster the knowledge
share and promote potential collaboration on cancer precision
medicine domestically and internationally, the first Interna-
tional Conference on Cancer Precision Medicine (IConCPM)
took place on September 22–24, 2016 in Tianjin, China. The
conference was hosted by the National Clinical Research Cen-
ter for Cancer (NCRCC), Chinese Anti-Cancer Association
(CACA), China Medicinal Biotechnology Association
(CMBA), Medical and Health Engineering Division of
Chinese Academy of Engineering (CAE), Tisch Cancer Insti-
tute at the Icahn School of Medicine at Mount Sinai, as well
as the National Foundation of Cancer Research (NFCR).
IConCPM was initiated by Prof. Xishan Hao, CAE academi-
cian from NCRCC and Prof. Raju Kucherlapati, member ofthe National Academy of Science of the United States (US)
from Harvard Medical School. As the conference chair, Prof.
Hao, together with co-chair Prof. Kucherlapati, delivered a
warm welcome speech. More than 300 people from all over
the world attended this conference and 23 talks were presented
at this meeting, focused on precision medicine in China. Then
Prof. Ping Wang, President of Tianjin Medical University
Cancer Institute and Hospital, and Zhaofeng Zhang, Director,
Division of Biotechnology and Medicine, Department of
Science and Technology for Social Development, Ministry of
Science and Technology of China, also gave their brief
remarks for welcome. The conference was preceded by a
next-generation sequencing (NGS) and bioinformatics analysis
workshop on Sept 22, covering topics from DNA/RNA extrac-
tion to sequencing data analysis. In this report, we provided a
short introduction on the talks and briefly recapitulated each
one of them referring to related publications whenever possi-
ble. At the end, we summarize this report with a few comments
on the success of IConCPM.
Topics
In the morning session on Sept 23, three academicians from
CAE or Chinese Academy of Sciences (CAS), China, and
one member of the National Academy of Science, US, pre-
sented their work on precision medicine. Prof. Hao overviewed
the current status of cancer care and precision medicine pro-
jects in China, touching global burden of cancer, status of can-
cer prevention and control, precision medicine and clinical
applications in cancer precision medicine. NCRCC, under
his leadership, has been committed to establishing precision
medicine research platform which includes cancer tissue bank,ces and
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ics core. This platform will offer risk prediction, early diagno-
sis, target therapy, prognosis evaluation, and drug
development to help realize the power of precision medicine.
Next, Prof. Webster Cavenee from the Ludwig Institute for
Cancer Research emphasized in his talk the necessity of inter-
national cooperation in cancer clinical trials for precision med-
icine. One single traditional clinical trial would need hundreds
to thousands of patients, but it may turn out impossible to
recruit enough patients for certain diseases. Take the US as
an example, there are simply not enough patients, say for
glioblastoma (GBM), in the entire country to do more than
an extremely small number of clinical trials, not even to men-
tion stratification on the basis of ethnicity or other factors. In
this context, GBM-AGILE (Adaptive Global Innovative
Learning Environment) was born to address these issues,
which has to accrue needed numbers of patients for combina-
tion trials. The goals of GBM-AGILE are rapid and efficient
testing of therapeutic agents and their combinations, as well
as developing databases of clinical trials, biomarkers, and
molecular data. This global platform will bring frontline trials
to a consortium of countries, providing sufficient patients to
stratify and test drug combinations. Afterward, Prof. Yixin
Zeng from the Beijing Hospital focused his talk on molecular
classification and personalized medicine. How does molecular
classification lead to precision medicine? The answer is to find
the right patients, give the right drug at the right timing. Prof.
Zeng took the example of nasal pharyngeal cancer (NPC) to
illustrate the importance of personalized prevention strategy
and molecular classification, which mainly refers to immune
markers including immune cell sub-typing, cytokines, major
histocompatibility complex (MHC) I and II molecules, B7
family and immune-related inhibitors. He concluded that pre-
cision medicine, on the basis of molecular classification, will
lead to future development of clinical practice and make mod-
ern medicine more cost-effective. In the following talk, Prof.
Qimin Zhan from the Peking University Health Science Center
introduced his research on genomic alterations of esophageal
squamous cell carcinoma (ESCC) [1]. Prof. Zhan and his group
identified 8 significantly-mutated genes in ESCC and muta-
tions in the gene encoding family with sequence similarity
135 member B (FAM135B) are correlated with clinical charac-
teristics. They also found miR-548k, a microRNA (miRNA)
that was amplified and overexpressed in ESCC, possesses
oncogenic characteristics in vivo and in vitro. In addition,
genetic alterations are also revealed in genes encoding compo-
nents of multiple pathways including Wnt pathway, Notch
pathway, RTK-Ras, and Akt pathways. Their findings support
the notion that cancer is now considered fundamentally as a
disease of genomic alteration. After the four presentations,
there was a panel discussion – Roles of technology, data and
analytics in precision medicine. Dr. Lynda Chin from Institute
for Health Transformation, University of Texas System and
Dr. Peter Bahrs from IBM Watson Health Implementations
Team co-chaired this section and discussed the roles of tech-
nology, cognitive analytics, and public–private partnerships
in precision medicine.
In the afternoon session on the first day (Sept 23), 11 speak-
ers were invited to share their insightful opinions or brilliant
work. Prof. Kucherlapati summarized the Precision Medicine
Initiative of the US, featured by disease prevention, detection,
and treatment through the precise manner. He also introducedthe Moon Shots Program with the ultimate goal to end
the threats of cancer. This program was launched by M. D.
Anderson Cancer Center in 2012. On January 12, 2016, Presi-
dent Obama announced a Cancer Moonshot initiative to accel-
erate cancer research, which aimed to make more therapies
available to more patients and improve our ability to prevent
cancer and detect it at an early stage. Next Qing Li, Director,
Science and Development Centre, the National Health and
Family Planning Commission of China, introduced the reform
of science and technology program management system and
the foundation of the several national-level projects. And in
the end, he shared his view on the China Precision Medicine
Initiative. Then Prof. Daniel Sulivan from the Moffitt Cancer
Center presented their practice of the precision medicine in
the Oncology Research Information Exchange Network
(ORIEN), which is a network of several major cancer centers
in the US, with ultimate goals to provide evidence for deci-
sion-making and clinical care. Following these talks was the
immunotherapy and chimeric antigen receptor T-cell
(CAR-T) session. First, Prof. Steven Burakoff from Mount
Sinai School of Medicine presented their work of identifying
hematopoietic progenitor kinase 1 (HPK1) as a novel
immunotherapy target [2]. Next Prof. Renier J. Brentjens from
the Memorial Sloan Kettering Cancer Center, who leads one
of the first teams conducting CAR-T therapy in the world,
introduced their latest clinical trials on several cancers with
diverse modifications of the therapeutic cells [3–8]. After the
tea break, Prof. Cheng Qian from the Third Military Medical
University shared their clinical practice with modified dendritic
cells (DCs) and CAR-T on several cancer types. Then Prof.
Chunrong Tong from the Lu Daopei Hematology Oncology
Center introduced their experience on utilization of anti-
CD19 CAR-T cells for refractory/relapsed b acute lym-
phoblastic leukemia. Next as a collaborator of Prof. Tong,
Prof. Hongsheng Zhang from the Tongji University School of
Medicine presented their translational research and clinical
application of CAR-T therapy. Prof. Weidong Han from the
Chinese PLA General Hospital then summarized their clinical
practice of CAR-T cell therapy on both hematologic cancer
and solid tumor [9–11]. Prof. Zhong Li from the Second
Military Medical University talked about his perspective on
cancer immunotherapy. At last, Prof. Xiubao Ren from the
Tianjin Medical University Cancer Institute and Hospital
summarized the overall clinical progress of CAR-T cells in
cancer treatment.
In the morning of Sept 24, Dr. Ying Wang, Secretary Gen-
eral of CACA, and Dr.Michael Wang from NFCR both intro-
duced the contribution of academic societies in precision
medicine. In her presentation, Dr. Wang introduced CACA,
the role of CACA in cancer prevention and control, as well
as the role of CACA in cancer precision medicine. Then Prof.
Bruce Johnson from the Harvard Medical School and Dana
Farber Cancer Institute gave his presentation about the impact
of genomic changes on precision medicine for lung cancer [12].
Mutations in the gene encoding epithelial growth factor recep-
tor (EGFR), rearrangements of the gene encoding anaplastic
lymphoma kinase (ALK), and other oncogenic drivers, such
as BRAF, are the most common genomic changes in lung can-
cer. The Lung Cancer Mutation Consortium (LCMC) is plan-
ning analyses on these genomic changes and will establish a
virtual database that may help doctors and researchers
determine the frequency of certain mutations and explore
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Wakai from Niigata University next introduced the genomic
sequencing for optimal cancer treatment in gastrointestinal
cancer. He and his group demonstrated concordance of Can-
cerPlex with whole-exome sequencing from the TCGA in iden-
tifying hypermutated samples and microsatellite instability in
multiple cancer types, such as colorectal and gastric cancers.
They also highlighted the clinical utility of CancerPlex in guid-
ing treatment strategies with targeted therapy in solid tumors,
thus demonstrating how to harness the power of NGS in actu-
alizing precision medicine. Prof. Mu-Sheng Zeng from Sun
Yat-sen University presented his work on advances of basic
and translational study of NPC. They found that expression
of B lymphoma Moloney murine leukemia virus insertion
region 1 homolog (Bmi-1) or human telomerase reverse tran-
scriptase (hTERT), and knockdown of p16 enabled immortal-
ization of nasopharyngeal epithelial cells (NPECs). Sphere-like
culture of Bmi-1 immortalized cells supported high efficiency
of cell-free infection of Epstein–Barr virus (EBV), an oncov-
irus for NPC. They also demonstrated that RNA binding
motif protein 24 (RBM24) played a role in NPC by modulat-
ing the stability of miRNAs and long non-coding RNAs. In
the next talk, Prof. Andreas Keller from Saarland University
focused on miRNAs and cancer. They found that blood-borne
miRNAs were stable and powerful biomarkers for early diag-
nosis and companion diagnostics in cancer that are currently
pushed from research to clinics. He also cautioned the biases
present when measuring microRNA expression from different
sources or using different platforms. These issues should be
well appreciated and taken into account for translation into
clinical practice. After the talk, there was a panel discussion
co-chaired by Prof. Qiang Li from Tianjin Medical University
Cancer Institute and Hospital and Prof. Xiaoming Zou from
EOC Pharma, discussing the target therapies and drug devel-
opment in the era of precision medicine.
In the afternoon session on the second day (Sept 24), the
meeting started with two panel discussions about genetic test-
ing for cancer and investments in precision medicine in China
which were chaired by Tuan Ha-Ngoc from KEW and Tom
Miller from Greybird Ventures, respectively. In the following
session chaired by Prof. Keller and myself, Zhimin Yang from
Center for Drug Evaluation, China Food and Drug Adminis-
tration, talked about issues that should be considered for
development and evaluation of oncology products in the per-
spective of precision medicine. She illustrated her viewpoint
on the model evolution of oncology product development,
precision medicine, development of clinical innovation prod-
ucts, as well as the considerations for development and eval-
uation under the new model for precision medicine. Prof. Yi
Zhao from Institute of Precision Medicine, CAS reported
his work on big data platform construction under the China
Precision Medicine Initiative, aimed to build the most com-
plete genetic library of the Chinese population. The confer-
ence ended with a panel discussion co-chaired by Prof. Hao
and Prof. Kucherlapati. Featuring the future of precision med-
icine in China, participants provided their comments to ques-
tions including (1) what technologies are for precision
medicine; (2) how these technologies can impact the patient
treatment today; (3) how to identify the right patients for
new trials; (4) who are going to pay; and (5) what China
can benefit from the lessons learnt in precision medicine
projects in the US.Conclusion
The conference ended successfully and has received numerous
positive feedbacks from the participants. The conference pro-
vided a perfect chance for overseas and domestic scientists
and physicians to communicate and share their understanding
and practice of the Precision Medicine. Meanwhile the confer-
ence provided a productive platform for elite from the related
fields to collaborate from decision making to drug develop-
ment and investment. Other than the informative talks and
insightful discussion, the conference organizers also made kind
arrangements in having slides in both English and Chinese
simultaneously with the live interpretation, making sure
smooth communication.
Given the emerging need of precision medicine in China,
the conference introduced overseas system and practice of pre-
cision medicine into China as examples. Involvement of people
with diverse roles in precision medicine from doctors, research-
ers, policy makers, industrialists to investors altogether would
help to find answers or address specific concerns for China as
raised during the conference, and hopefully result in a wider
and deeper collaboration among different parties along the
whole process of precision medicine for cancer clinical care.References
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